roche holdings ltd-spons adr
(RHHBYN:Mexico)
roche holdings ltd-spons adr (RHHBYN) Snapshot
|
Open
$780.00
|
Previous Close
$782.80
|
|
|
Day High
$782.80
|
Day Low
$780.00
|
|
|
52 Week High
05/15/13 - $786.76
|
52 Week Low
06/4/12 - $551.30
|
|
|
Market Cap
2.7T
|
Average Volume 10 Days
879.8
|
|
|
EPS TTM
--
|
Shares Outstanding
0.0
|
|
|
EX-Date
03/7/13
|
P/E TM
--
|
|
|
Dividend
$1.98
|
Dividend Yield
3.16%
|
Related News
roche holdings ltd-spons adr (RHHBYN) Related Businessweek News
roche holdings ltd-spons adr (RHHBYN) Details
Roche Holding AG operates in the fields of pharmaceuticals and diagnostics worldwide. It discovers, develops, and provides diagnostic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, and treatment of diseases. The company provides in-vitro diagnostics instruments and tests for the early detection and diagnosis of cancer. It is also involved in the research and development, and marketing of pharmaceutical products primarily in the therapeutic areas of oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, the company provides a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for the doctors; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. Further, the company offers integrated cobas, a solution for blood serum testing in commercial and hospital labs, medical centers, and laboratory networks. Roche Holding AG also offers various products for researchers in the areas of amplification, cell analysis, gene expression, genome sequencing, microarrays, nucleic acid purification, protein analysis, real-time PCR systems, and transfection. It has strategic alliances with Technoclone and Med Fusion, LLC, as well as a strategic collaboration with AREVA Med LLC. The company was founded in 1896 and is headquartered in Basel, Switzerland.
roche holdings ltd-spons adr (RHHBYN) Top Compensated Officers
roche holdings ltd-spons adr (RHHBYN) Key Developments
Macrocyclics, Inc. announced new collaborative research agreement with Roche for the continued development of novel chelating agents designed specifically by Macrocyclics for Roche's applications. The new project will build on established expertise related to lead-212 (212Pb) and novel chelate architecture for radioimmunotherapy. The high level of synergy between the two organizations is expected to speed up the clinical development process.
Roche Holding AG (SWX:ROG) is considering divesting its blood glucose meters business, three people close to the matter said. One of the people stated that talks regarding sale of the unit are still at initial stages and a deal may not materialize. Two of the people stated that there are only a few companies that sell blood glucose meters, including Medtronic Inc and Johnson & Johnson, which would make logical buyers.
Roche Holding AG Presents at UBS Global Healthcare Conference, May-22-2013 10:30 AM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Alan Hippe, Chief Financial and IT Officer.
| Recently Viewed | |||
| RHHBYN:MM | $782.80 MXN | 0.00 | |
| Company | Last | Change |
| GlaxoSmithKline PLC | 1,750 GBp | +7.50 |
| Merck & Co Inc | $47.16 USD | -0.17 |
| Novartis AG | SFr.71.25 CHF | -0.20 |
| Pfizer Inc | $29.04 USD | -0.07 |
| Sanofi | €84.51 EUR | -0.30 |
| View Industry Companies | ||
Industry Analysis
RHHBYN
Industry Average
| Valuation | RHHBYN | Industry Range |
| Price/Earnings | 21.6x |
|
| Price/Sales | 4.3x |
|
| Price/Book | 14.1x |
|
| Price/Cash Flow | 17.7x |
|
| TEV/Sales | 2.7x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact ROCHE HOLDINGS LTD-SPONS ADR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








